Navigation Links
Sangamo BioSciences Announces Presentation of Positive Clinical Data From Novel ZFN Therapeutic Approach for the Treatment of HIV/AIDs at Conference for Retroviral and Opportunistic Infections
Date:2/28/2011

fied cells behave like unmodified cells and traffic to the gut mucosa. In addition, we observed selective expansion of ZFN-modified cells in the gut mucosa, a major reservoir of HIV in the body, suggesting that these cells are protected from HIV and selectively enrich in the presence of the virus. These data are consistent with our preclinical findings†. The data also underscore our decision to expand our clinical studies to populations of HIV-infected individuals that have active viral replication and thus higher viral loads and retain immune reactivity to HIV.  From such studies we will be able to assess the effect of ZFN-CCR5-modified T- cells on overall T-cell numbers and the course of the viral infection."

"This presentation is a terrific beginning to a transformational year of clinical data for Sangamo," stated Edward Lanphier, Sangamo's president and chief executive officer. "Later in 2011, we expect to present additional clinical data from our ZFP Therapeutic® programs in HIV/AIDs as well as data from our Phase 2b clinical trial (SB-509-901) of a first-in-class, disease modifying-approach to diabetic neuropathy. The data presented at CROI are the latest example of our substantial progress towards our goal of establishing ZFP Therapeutics as a new and highly differentiated class of human pharmaceuticals to address unmet medical needs."

† (Nat Biotechnol. 2008 Jul;26(7):808-16  Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases).

About the SB-728-T Clinical Trial (SB-728-902)

The study is an open-label Phase 1 clinical trial to evaluate the safety and tolerability of single infusions of an escalating dose of an autologous (a patient's own) CD4+ T-cell product genetically modified at the CCR5 gene by CCR5-specific ZFNs (SB-728-T). The trial will enroll a total of nine HIV-infected subjects (three cohorts of three subjects each) who have sub-optimal
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
(Date:8/29/2014)... , Aug. 29, 2014  In part ... to leverage a hospital pharmacy as a strategic asset, ... national practice leader for Cardinal Health,s Innovation Delivery Solutions ... care can benefit both hospitals and patients. ... only one part of their job in a value-based ...
(Date:8/29/2014)... Aug. 29, 2014 Research and Markets ... Soft Tissue Repair Devices Market 2014-2018" report to ... the mass of cells that connect, support, or surround ... such as tendons, ligaments, cartilage, fascia, and other fibrous ... these tissues with age result in wear and tear ...
Breaking Medicine Technology:Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 2Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 3Five Ways Hospital Pharmacies Can Fulfill Their Quality Care Mission 4Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... Minn., Oct. 14 AbbeyMoor Medical Inc. ... CPT code by the American Medical Association (AMA) for ... action, effective in January 2010, upgrades The Spanner from ... Category I procedure code for established procedures. This major ...
... 14 CardioGenics Holdings Inc. (OTC Bulletin Board: JAGH), provides ... in the company,s name, ticker symbol and CUSIP number. ... FINRA all documentation requested in connection with the name change, ... number for the company,s common shares. FINRA is working ...
Cached Medicine Technology:AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 2AbbeyMoor Medical Receives Category I CPT(R) Code for The Spanner(TM) Prostatic Stent Procedure 3CardioGenics Holdings Inc. Provides Update on FINRA Submission Regarding Name Change 2
(Date:8/30/2014)... (PRWEB) August 30, 2014 "I had a ... of her crutches," said an inventor from Wetumpka, Ala. "In ... and sounds of the shore, I came up with a ... , She created a prototype for the patent-pending Deezers to ... enables the individual to use crutches, walkers, or canes at ...
(Date:8/30/2014)... 30, 2014 In today’s world, a ... difficult to get. Snoring and sleep apnea (a medical ... stops) robs people and their bed partners of the ... to 45% of the population snores and 20 million ... Of these, only 10% have been diagnosed and treated; ...
(Date:8/30/2014)... 30, 2014 The new review published by ... created by Karen Brimeyer, who wanted to make her guide ... This guide is now easy to find in the form ... this guide, the author of the new method shares all ... Daily Gossip writes in its review that the leaky gut ...
(Date:8/30/2014)... LiveStreamingFitness.com, a company dedicated to providing live ... resources, is proud to announce it has been recognized as ... fitness solutions by ABC’s Good Morning America. ... Good Morning America, “Live Streaming Fitness is the hottest new ... by streamlining your workout…to boot camp at Life Streaming Fitness ...
(Date:8/30/2014)... August 30, 2014 When a prominent bank ... as happened on Wednesday, August 27th, when news began surfacing ... JPMorgan Chase & Co and at least one other ... actually investigating attacks on seven prominent banks , everyone ... be affected, and the buzz quickly goes viral. Bloomberg ...
Breaking Medicine News(10 mins):Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:LiveStreamingFitness.com is New Trend In Fitness 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5
... at Harvard University have created a laboratory model using ... stages of ovarian cancer metastasis. "We were ... for the force-dependent processes associated with metastasis," said Joan ... Harvard University. These findings are published in ...
... awarded Penn State, Penn State Milton S. Hershey Medical ... million, five-year grant designed to accelerate the translation of ... This competitive Clinical and Translational Science Award (CTSA) will ... (CTSI), a collaboration of many Penn State colleges and ...
... , TUESDAY, June 14 (HealthDay News) --,Scheduling classes later in ... in the morning, but it may also encourage them to ... that undergrads whose classes started later were more likely to ... times predicted more drinking, more sleep time and modestly lower ...
... liver fibrosis, such as liver stiffness measurement or the ... C, according to a new study in Gastroenterology ... (AGA) Institute. "Liver stiffness measurement and/or the ... hepatitis C, regardless of the stage of the disease," ...
... 15, the Lymphoma Research Foundation (LRF), in collaboration with ... Center, will bring together lymphoma experts to discuss the ... This event is the final installation of LRF,s 2010-2011 ... series focused on the diagnosis and treatment of lymphoma ...
... Tiny fibres used to strengthen everyday products such as bicycle ... involved in their manufacture. Certain types of carbon nanotubes ... human hair could cause cancer in the lining of ... study in mice found that while short carbon nanotubes appeared ...
Cached Medicine News:Health News:Penn State receives $27.3 million NIH grant 2Health News:Penn State receives $27.3 million NIH grant 3Health News:Penn State receives $27.3 million NIH grant 4Health News:College Students Who Sleep in Drink More, Study Less 2Health News:Noninvasive liver tests may predict hepatitis C patient survival 2Health News:Lymphoma Research Foundation and John Theurer Cancer Center collaborate for Lymphoma Rounds program 2
... while minimizing the pain of ... safety-engineered BD Microtainer Genie Lancet. ... offers a full range of ... blood collection and protects the ...
The DiaSTAT™ is an automated liquid chromatography system designed for the rapid and automated analysis of hemoglobin A1C. Ideal for low and ,medium volume testing environments....
The HEMOCHRON Jr. Signature+ Microcoagulation System offers point-of-care monitoring with numerous features to meet the needs of each individual department, as well as the needs of regulatory complia...
Inquire...
Medicine Products: